[Abstract] The in vitro limiting dilution assay is used to determine the colorectal cancer initiating cell (CC-IC) frequency of a CC-IC enriched suspension culture, grown in growth factor enriched serum free media. The in vivo limiting dilution assay is used to determine the colorectal cancer initiating cell frequency of a primary colorectal cancer sample or an established suspension cell line using immunocompromised murine xenograft models. In vitro and in vivo limiting dilution assays (LDAs) can be used to determine the effect of a specific treatment or genetic knockdown strategy on the initiating cell frequency of a population of CC-ICs or colorectal cancer sample, respectively.
http://www.bio-protocol.org/e1659 Vol 11. Using a syringe (without a needle), aspirate the matrigel and deposit a small drop of gel (~200 μl) into the base of syringe.
12. Thoroughly mix the desired cell solution before adding 30 μl to the droplet of matrigel.
13. Carefully reinsert the plunger, making sure not to expel the matrigel solution out of the syringe.
14. Keep the loaded syringes on ice until ready to use. 2. Inject mice subcutaneously with cells on both the right and left flank, using a new syringe for each injection (see Figure 2) . Each mouse should have two injections, one on each flank (see Table 2 ). a. Penicillin-streptomycin-amphotericin B (1%) 5 ml/500 ml b. L-glutamine (2 mM) 5 ml/500 ml c. Non-essential amino acids (1x) 5 ml/500 ml d. Sodium pyruvate (1 mM) 5 ml/500 ml e. HEPES (1x) 5 ml/500 ml f. Heparin sodium salt (4 μg/ml) from porcine intestinal mucosa g. Lipids 1 ml/500 ml h. Human Epidermal Growth Factor Recombinant (EGF) (20 ng/ml) i. Human basic Fibroblast Growth Factor Recombinant (bFGF) (10 ng/ml) j. N2 supplement-A 5 ml/500 ml k. NeuroCult SM1 Neuronal 2 ml/500 ml
